L-Dopa
PreclinicalSmall molecule
Merck & Co.L-Dopa is one of 19 small molecule programs targeting Substance Abuse. It is currently in Preclinical.
1
Indications
16
Total Trials
2
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Substance Abuse
#DrugCompanyPhaseTrials
1Exelon
NovartisApproved
Namenda
AbbVieApproved
Abilify
OtsukaApproved
Strattera
MMap77
Approved
Chantix
PPrism Pharmaceuticals
Approved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Oxycontin
PProtega
Approved
Mirapex
Boehringer IngelheimApproved
Vyvanse
TakedaPreclinical
Revia
TevaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Parkinson's Disease3 trials
Parkinson2 trials
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia
Unknown status·—··NCT02578849·45 enrolled
Depression2 trials
Oxytocin1 trial
Oxytocin and Dopamine's Effect on Vicarious Optimism
Completed·—·N/A·NCT03891095·156 enrolled
6 more indications
Deep Brain Stimulation1 trial
Cerebral Palsy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for L-Dopa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company